Actively Recruiting
Observational Study of Treatment and Outcomes in Adults with Advanced Lung Cancer Having MET Mutation
Led by Hunan Province Tumor Hospital · Updated on 2024-09-19
200
Participants Needed
1
Research Sites
25 weeks
Total Duration
AI-Summary
What this Trial Is About
This research aims to understand treatment patterns and effectiveness in patients with advanced lung cancer who have a MET mutation. It is an observational study conducted in a way that does not interfere with patients current medical care. Data will be collected both retrospectively from past treatments and prospectively from future treatments, with patient enrollment occurring after genetic analysis of tumor tissue and informed consent. The study observes patients receiving various first-line treatments including immunotherapy with or without anti-angiogenic therapy or chemotherapy, as well as treatments with savolitinib, glumetinib, or bozitinib. No new drugs or tissue sampling are introduced as part of the study. Information is gathered regularly every three months to track patient progress. Participants will be monitored for outcomes such as progression-free survival and overall survival over approximately 4.5 years. Additional assessments include the relationship between genetic profiling and these outcomes and overall response rate. The study collects data in an epidemiological manner to better understand real-world treatment effectiveness without altering patients ongoing treatments.
CONDITIONS
Brief Title
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
Research Team
Y
Yongchang Zhang, MD
N
Nong Yang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
